Cerenis Therapeutics Announces That CARAT Phase 2 Study Data on CER-001 Have Been Presented At ACC Annual Meeting 2017

Cerenis Therapeutics, an international biopharmaceutical company dedicated to the discovery and development of innovative therapies for treating cardiovascular and metabolic diseases, announces that CARAT Phase 2 Study data on CER-001 in post-acute coronary syndrome (ACS) patients have been presented at the Annual American College of Cardiology (ACC) Scientific Sessions in Washington DC, USA.

Source:
www.businesswire.com/news/home/20170320005384/en/Cerenis-Therapeutics-Announces-CARAT-Phase-2-Study